Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Asset disposition
Director comp.
LEXICON PHARMACEUTICALS, INC. (LXRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
07/31/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/12/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
Docs: "THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT"
06/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among Lexicon Pharmaceuticals, Inc. and Citigroup Global Markets Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein",
"Opinion of Vinson & Elkins L.L.P",
"Purchase Agreement, among Lexicon Pharmaceuticals, Inc. and Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Mr. Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A",
"LEXICON ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT"
06/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/01/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
05/31/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK"
05/31/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
05/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/08/2023 8-K/A Submission of Matters to a Vote of Security Holders
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/17/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/17/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/03/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
Docs: "LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
01/04/2023 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
09/02/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT"
08/09/2022 SC 13D/A Invus, L.P. reports a 47.6% stake in Lexicon Pharmaceuticals, Inc.
08/03/2022 D Form D - Notice of Exempt Offering of Securities:
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/02/2022 8-K Quarterly results
Docs: "LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
08/01/2022 SC 13D/A Invus, L.P. reports a 47.6% stake in Lexicon Pharmaceuticals, Inc.
07/29/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among Lexicon Pharmaceuticals, Inc. and Citigroup Global Markets Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein",
"Opinion of Vinson & Elkins L.L.P",
"Purchase Agreement, among Lexicon Pharmaceuticals, Inc. and Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A",
"Purchase Agreement, among Lexicon Pharmaceuticals, Inc. and Invus US Partners LLC",
"LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK",
"LEXICON ANNOUNCES PRICING OF $85.0 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT",
"LEXICON ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR SOTAGLIFLOZIN TO TREAT HEART FAILURE"
07/29/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/27/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/30/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy